People have practiced ozone therapy in medical settings for many years. However, its use is now controversial amid safety concerns. The Food and Drug Administration (FDA) has warned against using ...

The AI-driven tools are getting better at recommending biomarker-targeted therapies, but experts warn they aren't ready for prime time.

TUESDAY, Feb. 4, 2025 (HealthDay News) — For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard chemotherapy (modified folinic acid [or ...

Interferon beta injectable drugs were the first DMTs approved for MS treatment. The injections help change the course of active relapsing-remitting MS and secondary progressive MS. If a person has ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer last month, and it already has survival data that could see that converted ...

For lung cancer, we are in the process of shifting to immunotherapy and targeted therapy based on gene panel tests. It has improved the survival rate and period, as well as the patients' quality ...

Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...

“The BRAFTOVI regimen is emerging as a new standard of care as the first targeted therapy approved for use as early as first-line for patients with mCRC with a BRAF V600E mutation. We look ...

This study is the first experimental demonstration that CTCs isolated from patients with CRC express cancer stem cell phenotype and can be used to determine drug sensitivity ... BRAF-mutated cells in ...